Ranbaxy

7,088 views
6,736 views

Published on

Published in: Education, Business
0 Comments
7 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
7,088
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
0
Comments
0
Likes
7
Embeds 0
No embeds

No notes for slide

Ranbaxy

  1. 1. GROUP MEMBERS Priya Doshi Richa Talati Ronak Soni Shibin Jacob Sneha kapadia Vikas verma
  2. 2. TABLE OF CONTENTIntroduction, Industry Profile, Company Profile, Vision, Mission –
  3. 3. INDUSTRY PROFILE The Indian Pharmaceutical Industry today is in the first rank of India’s science based industries. The Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units.
  4. 4. COMPANY PROFILE Ranbaxy Laboratories Limited, Indias largest pharmaceutical company. Ranked 8th amongst the global generic pharmaceutical companies. The Company has a global footprint in 49 countries. World-class manufacturing facilities in 11 countries and serves customers in over 125 countries. R&D has a pool of over 1,200 scientists engaged in research.
  5. 5. Perhaps the largest front-end in the generic industry BRICS Other Emerging Markets • No. 1 in India • 43/54 countries in Africa • Large, reputed player in • Latam & Asia Pacific: CIS; growing rapidly long standing presence; • No. 6 in Brazil good understanding; • No. 5 in S. Africa robust businesses North America & Europe Japan • Pioneer entrant from • Well established India • 23/25 EU markets • Strong local presence • No. 1 Generic player in • Canada: New market, Romania growing rapidly Ground presence in 49 countries; products sold in 125
  6. 6. MISSION To become a research based internationalpharmaceutical company.
  7. 7. VISION Achieving customer satisfaction is fundamental to our business. Provide product and service of the highest quality. Manage our operation with high concern for strategy and environment. Be a responsible corporate citizen
  8. 8. MILESTONES Ranbaxy entered in Golden Jubilee year. For the year 2008, the Company recorded Global Sales of US $ 1,682 Mn Ranbaxy launches First to file (FTF) product , Donepezil hydrochloride Tablets 5 mg and 10 mg with 180 days market exclusively in the U.S. healthcare system. Ranbaxy delivered quarterly sales of over US $ 500Mn for the first time.
  9. 9. Marketing
  10. 10. Strengths Weakness• Low cost of production • Low on Capital Goods• Efficient technology for • Low on key R&D large no. of Generics • Less usage Bio-• Skilled manpower technology for New Drug Discovery Systems Opportunities Threats• Growing attention for health • High cost of discovering new• New therapy approaches products• Globalization • Stricter registration• Growing income-levels procedures • High entry cost in new markets
  11. 11.  Among top 10 Global generic drugs company. Manufacturing operations in 11 countries, ground presence in 49 countries and serves 125+ countries. Expanding international portfolio of affiliates and JVs International business generate 80% sales. Strong market presence and distribution network. State-of-the-art multi-disciplinary research facilities.
  12. 12.  Flexible and efficient supply chain structure ensures stable access to raw materials, systematic manufacturing and timely, reliable delivery. Ranbaxy- Daiichi Sankyo Tie-upRanbaxy- access to Daiichi’s expertise in researchDaiichi - benefit from low-cost production
  13. 13. KEY COMPETENCIES
  14. 14. EMPLOYERSSHAREHOLDERS RANBAXY INVESTORS CUSTOMERS
  15. 15. HR
  16. 16. EMPLOYER EXPECTATION Good working condition Employee satisfaction toward salary. Proper assigned of works and goals.
  17. 17. RETENTION POLICY Training programs Management trainee programs. Through salaries and various other benefit.
  18. 18. TRAINING AND DEVELOPMENT There basic is to understand the business through lecturer and interactive session. Project work in various areas of the key function, across different location. Self –awareness session also provided. Self development with training on key behavior attitudes.
  19. 19. PERFORMANCE APPRAISAL It is used as a to measure the performance of employee s in the organization to check the progress towards the desired goals and aims. Performance appraisal helps to rate the performance of the employees and evaluate their contribution towards the organizational goals. Performance appraisal takes into account the past performance of the employees and focuses on the improvement of the future performance of the employees.
  20. 20. HEALTH AND SAFETY MEASURE They are totally committed to maintain high standards of health and safety at the workplace . They try to be sensitive to protection of the environment by responsible management of waste and pollution.
  21. 21. Finance
  22. 22. Revenue Breakdown Global Revenue RoW $1,667 $203, +6 Asia $1,619 Europe $1,400 % $465, +3$1,339 $328, - % 10% North America CIS $4432006 2007 2008 2009 (F)* $111, +24 , +6% % Favourable Market Mix  Revenues spread across geographies  Growing share of high growth, sustainable branded business in Emerging Markets  Substantial presence in regulated, western markets: high volume base business + large Para-IV / FTF opportunities
  23. 23. COST DRIVERS Raw material R&D Patent of product ( Process patent & Drug patent) Packaging Logistics Ware housing ( self & contracted )
  24. 24. http://www.ranbaxy.com/investorinformati on/irglance.aspx
  25. 25. LastquarterDecember2010
  26. 26. RECENT NEWS
  27. 27. MYLAN SUES US FDA TO BLOCK LIPITOR LAUNCHBY RANBAXY MARCH 21, 2011 Source: Business standard of 22nd March 2011
  28. 28. MERCK, RANBAXY DRUG DEVELOPMENT DEAL CALLEDOFF JANUARY 6, 2011
  29. 29. CONCLUSION
  30. 30. BIBLIOGRAPHY www.ranbaxy.com www.moneycontrol.com www.ndtvprofit.com

×